News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,587 Results
Type
Article (41926)
Company Profile (333)
Press Release (665328)
Section
Business (210166)
Career Advice (2080)
Deals (36583)
Drug Delivery (100)
Drug Development (82854)
Employer Resources (171)
FDA (16491)
Job Trends (15360)
News (355493)
Policy (33832)
Tag
Academia (2574)
Alliances (51187)
Alzheimer's disease (1280)
Approvals (16451)
Artificial intelligence (158)
Bankruptcy (362)
Best Places to Work (11716)
Biotechnology (215)
Breast cancer (192)
Cancer (1400)
Cardiovascular disease (116)
Career advice (1741)
Cell therapy (285)
Clinical research (66247)
Collaboration (498)
Compensation (265)
COVID-19 (2612)
C-suite (111)
Data (1402)
Diabetes (178)
Diagnostics (6255)
Earnings (86580)
Employer resources (149)
Events (112873)
Executive appointments (405)
FDA (17189)
Funding (437)
Gene therapy (206)
GLP-1 (633)
Government (4453)
Healthcare (18879)
Infectious disease (2705)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16621)
Job creations (4052)
Job search strategy (1488)
Layoffs (439)
Legal (8327)
Lung cancer (200)
Lymphoma (100)
Manufacturing (216)
Medical device (13299)
Medtech (13304)
Mergers & acquisitions (20120)
Metabolic disorders (478)
Neuroscience (1612)
NextGen Class of 2024 (6625)
Non-profit (4515)
Northern California (1708)
Obesity (272)
Opinion (207)
Patents (123)
People (58423)
Phase I (20519)
Phase II (29149)
Phase III (21858)
Pipeline (517)
Postmarket research (2651)
Preclinical (8730)
Radiopharmaceuticals (241)
Rare diseases (276)
Real estate (6240)
Regulatory (22526)
Research institute (2359)
Resumes & cover letters (358)
Southern California (1476)
Startups (3712)
United States (15425)
Vaccines (583)
Weight loss (197)
Date
Today (127)
Last 7 days (597)
Last 30 days (2409)
Last 365 days (35839)
2024 (35679)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35771)
2017 (33138)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (203)
Asia (40147)
Australia (6423)
California (3857)
Canada (1463)
China (314)
Colorado (175)
Connecticut (181)
Europe (85484)
Florida (539)
Georgia (136)
Illinois (397)
Indiana (233)
Maryland (641)
Massachusetts (3020)
Michigan (177)
Minnesota (292)
New Jersey (1125)
New York (1097)
North Carolina (761)
Northern California (1708)
Ohio (146)
Pennsylvania (934)
South America (1158)
Southern California (1476)
Texas (564)
Utah (109)
Washington State (408)
707,587 Results for "biocryst pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
BioCryst to Present at Upcoming May 2024 Investor Conferences
BioCryst Pharmaceuticals, Inc. announced that the company will present at the following conferences.
May 7, 2024
·
1 min read
Bio NC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 74,875 shares, and restricted stock units covering an aggregate of 39,050 shares, of BioCryst common stock.
June 4, 2024
·
1 min read
Bio NC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 79,575 shares, and restricted stock units covering an aggregate of 42,400 shares, of BioCryst common stock.
May 3, 2024
·
1 min read
Press Releases
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
November 18, 2024
·
5 min read
Business
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
BioCryst Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 6, 2024
·
14 min read
Press Releases
BioCryst to Present at Upcoming Investor Conferences
November 6, 2024
·
1 min read
Business
BioCryst to Report First Quarter 2024 Financial Results on May 6
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.
April 22, 2024
·
1 min read
Bio NC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2024
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 43,975 shares, and restricted stock units covering an aggregate of 30,625 shares, of BioCryst common stock.
April 3, 2024
·
1 min read
Bio NC
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
BioCryst Pharmaceuticals Inc. announced that new data on oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema will be presented at the European Academy of Allergy and Clinical Immunology meeting in Valencia, Spain from May 31 to June 3, 2024.
May 14, 2024
·
5 min read
Policy
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Pharmaceuticals, Inc. announced that the Brazilian Health Regulatory Agency has granted approval for oral, once-daily ORLADEYO® for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older.
April 17, 2024
·
6 min read
1 of 70,759
Next
